Wren Therapeutics Announces Publication in Nature Research Journal

Paper demonstrates predictive capability of chemical kinetics in assessing clinical-stage molecules for Alzheimer’s disease (“AD”)

  • Significant paper published in Nature Structural and Molecular Biology
  • Co-authored by Wren’s scientific founders and senior Biogen scientists
  • Aducanumab compared, in a blinded study, to three clinical-stage antibodies using chemical kinetics
  • Only aducanumab dramatically reduces the flux of amyloid-β oligomers, a key neurotoxic species associated with AD
  • Wren advancing its own lead small molecule programs against amyloid-β and α-synuclein using the same kinetics approach
  • Wren to nominate clinical candidate for AD in the first quarter of 2021
  • Other targets including TDP-43, tau and IAPP in earlier stage discovery


CAMBRIDGE, United Kingdom, September 28, 2020 – Wren Therapeutics, (“Wren”, the “Company”), a biopharmaceutical company pioneering a unique approach to drug discovery, today announces that a research paper entitled “Kinetic fingerprints differentiate the mechanisms of anti-Aβ antibodies” has been published in Nature Structural & Molecular Biology, a prestigious scientific journal. The paper was co-authored by Wren’s scientific founders together with senior scientists at Biogen.